005690 — Pharmicell Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Pharmicell Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	32,482	37,752	51,812	60,182	56,227
Cost of Revenue
Gross Profit	13,031	17,779	23,708	23,820	15,492
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	30,582	31,210	43,949	51,614	53,400
Operating Profit	1,900	6,542	7,863	8,568	2,828
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,443	5,242	9,451	5,969	4,732
Provision for Income Taxes
Net Income After Taxes	4,347	5,242	9,451	10,885	3,578
Net Income Before Extraordinary Items
Net Income	4,347	5,242	9,451	10,885	3,578
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,347	5,242	9,451	10,885	3,578
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	73.1	98.9	167	185	39.5
Dividends per Share